Skip to main content
OpenTrials
Completed

NCT Number: NCT05224947

Gastric Layering and Monitoring II

Rationale: Results from a previous study suggest that gastric layer formation, which is caused by emulsion instability as a result of gastric acidification/digestion, is different between breastmilk and infant formula. The current study focusses on further understanding of these differences by investigating the effect of formula composition.

Objective: To investigate the effect of infant formula composition on intragastric behavior, gastric emptying and postprandial plasma parameters.

Study design: Double-blind cross-over study with two treatments.

Study population: 20 healthy normal-weight males, aged 18-45 y.

Intervention: After an overnight fast, participants will drink sufficient volume of one of the two IFs which differ in composition. Gastric content will be monitored using Magnetic Resonance Imaging (MRI). MRI scans will be done and blood samples will be taken for subsequent analyses at baseline and post prandially .

Main study parameters/endpoints: The primary outcome is gastric behavior. Secondary outcomes are total gastric content volume over time and blood parameters.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The risks associated with participation are low, as both phlebotomy and MRI are eminently safe medical techniques. In addition, the test formula are safe. Each participant will participate in 2 sessions, which require an overnight fast, 9 blood withdrawals (in total 120 mL per visit) and multiple MRI scans over a period of approximately 2 hours. These measurements are non-invasive and carry minimal risk. The burden of the sessions is most likely related to mild discomfort as they have to lie still in the MRI for two hours. This will be minimized by the soft mattress on the bed of the MRI, leg rest and a pillow underneath the head.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infant Formula

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Wageningen University & Research

Wageningen, Gelderland, 6708WE, Netherlands

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male
  • Apparently healthy (self-reported)
  • Willing to be informed about incidental findings of pathology
  • Willing to comply with the study procedures

Exclusion criteria

  • Allergy or intolerance for cow milk, lactose, soy and/or fish (self-reported)
  • Gastric disorders or regular gastric complaints, for example heart burn
  • Use of medication which alters the normal functioning of the stomach, such as: Medical drug use that influences the GI tract's normal function, e.g. motility, pH etc.: among others use of protein pump inhibitors, antacids, anti-depressants etc. (judged by study doctor)
  • Medical drug use that influences the GI tract's microbiota: antibiotic use within one month prior to the pre-study screening day (judged by study doctor)
  • Smoking (>2 cigarettes a week)
  • Drinking more than 14 glasses of alcohol a week
  • Having given a blood donation in the past two months
  • Hb value below 8.4 mmol/L (as measured with finger-prick method at screening)
  • Having a contra-indication to MRI scanning, including, but not limited to:
  • Pacemakers and defibrillators
  • Intraorbital or intraocular metallic fragments
  • Ferromagnetic implants
  • Claustrophobia
  • Participating in other research during the study period
  • Being an employee or student of the division of human nutrition and health
  • Not having a general practitioner

Treatment and study plan

Infant Formula

Other

Two infant formulas differing in composition

Primary outcomes

  1. Gastric layer formation over time (mL) measured with MRI

    Time frame: 2 hours

Secondary outcomes

  1. Total gastric content volume over time (mL)

    Time frame: 2 hours

  2. Concentration of glucose in blood over time

    Time frame: 2 hours

  3. Concentration of insulin in blood over time

    Time frame: 2 hours

  4. Concentration of free fatty acids in blood over time

    Time frame: 2 hours

  5. Concentration of metabolites in blood over time measured with NMR (analysed by Nightingale: 'blood biomarker analysis service' )

    Time frame: 2 hours

Other outcomes

  1. Verbal ratings of hunger, fullness, bloating and nausea.

    Time frame: 2 hours

    Rated on a scale of 0-100, indicating 'not at all' to 'very much' respectively.

Sponsors and collaborators

Lead sponsor

Wageningen University

Other

Collaborators

  • FrieslandCampina

Registry information

Acronym: GLAM-II

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Feb 4, 2022
Registry last updated
Apr 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.